Parabilis Medicines
Creating extraordinary medicines
Cambridge, United States · Founded 2021 · $812.0M raised
- Headquarters
- Cambridge, Massachusetts
- Employees
- 201–500
- Founded
- 2021
- Business Model
- B2B
- Website
- parabilismed.com
- Total Funding
- $812.0M
- Last Round
- $305.0M Series FJan 2026
- Rounds
- 7
About
Parabilis Medicines is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for people living with cancer and other severe diseases. The company has pioneered a new category of ultra-tunable peptide therapeutics called Helicons, which combine the strengths of small molecules and monoclonal antibodies to achieve outcomes previously considered impossible. Parabilis's custom-built research engine is designed to tackle previously undruggable biology targets, and the company has demonstrated clinical proof-of-concept for its approach. Headquartered in Cambridge, Massachusetts, Parabilis raised $305M in early 2026 to advance its pipeline of Helicon-based cancer therapies.
Summary
Parabilis Medicines is a Biotech company based in Cambridge, United States, founded in 2021. It has raised $812.0M in total across 7 rounds, most recently a $305.0M Series F round in Jan 2026. Investors include RA Capital Management, Janus Henderson Investors and Fidelity Management.
Tech & App Stack
9 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jan 2026
Sign up to see all 7 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Alphabet-backed biotechnology company researching biology of aging and developing interventions t...
BridgeBio makes targeted treatments for genetic diseases.
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...